While peptide-based cancer vaccines had limited success through the years, the survival benefit gained from the gp100-209:217(210M) melanoma epitope vaccine trial was received with much enthusiasm, and has reinvigorated interest in peptide vaccines for cancer immunotherapy. The gene discussed is PMEL; the disease is cancer.